A 32-year-old pregnant woman (24 weeks gestation) from Bangalore presents with a 3-day history of low-grade fever, maculopapular rash on her face and trunk, and mild conjunctivitis without exudate. She has no joint pain or bleeding manifestations. Laboratory tests show normal platelet count (210,000/μL), negative dengue NS1, and negative Chikungunya IgM. Obstetric ultrasound shows normal fetal biometry and amniotic fluid volume. What is the most appropriate next step in management?

Explanation

## Zika Virus Infection in Pregnancy: Management Strategy ### Clinical Presentation Consistent with Zika **Key Point:** The triad of **low-grade fever, maculopapular rash, and conjunctivitis without exudate** in the absence of thrombocytopenia and negative dengue/Chikungunya serology strongly suggests **Zika virus infection**. ### Why This Patient Likely Has Zika | Feature | Finding | Significance | |---------|---------|-------------| | **Fever** | Low-grade, 3 days | Zika typically causes mild systemic symptoms | | **Rash** | Maculopapular, face and trunk | Characteristic Zika rash | | **Conjunctivitis** | Non-exudative | Zika causes conjunctivitis WITHOUT exudate (unlike dengue) | | **Arthralgia** | Absent | Zika causes only mild arthralgia, if any | | **Platelet count** | Normal (210,000) | Zika does not cause thrombocytopenia (dengue does) | | **Dengue NS1** | Negative | Excludes dengue | | **Chikungunya IgM** | Negative | Excludes Chikungunya | | **Pregnancy status** | 24 weeks | Second trimester; risk of congenital Zika syndrome | ### Congenital Zika Syndrome: Critical Considerations **High-Yield:** Zika virus is **teratogenic**, particularly in the **first and second trimesters**. Congenital Zika syndrome includes: 1. **Microcephaly** (most characteristic) 2. Intracranial calcifications 3. Cortical atrophy 4. Ventriculomegaly 5. Ocular abnormalities (chorioretinitis, optic nerve hypoplasia) 6. Arthrogryposis 7. Growth restriction **Clinical Pearl:** Vertical transmission can occur at ANY trimester, but the risk and severity of fetal abnormalities are highest in the **first trimester** (up to 15% risk of microcephaly). Risk decreases in second and third trimesters but remains significant. ### Appropriate Management Algorithm ```mermaid flowchart TD A[Suspected Zika in pregnancy]:::outcome --> B[Confirm diagnosis]:::action B --> C[RT-PCR serum/urine]:::action B --> D[Serology: IgM/IgG]:::action C --> E{RT-PCR positive?}:::decision E -->|Yes| F[Confirmed Zika]:::outcome E -->|No| G{IgM positive?}:::decision G -->|Yes| F G -->|No| H[Alternative diagnosis]:::outcome F --> I[Serial fetal ultrasound]:::action I --> J{Microcephaly or<br/>CNS abnormalities?}:::decision J -->|Yes| K[Detailed fetal MRI<br/>Pediatric neurology consult]:::action J -->|No| L[Reassurance<br/>Continue monitoring]:::action K --> M[Counselling on prognosis<br/>Delivery planning]:::action L --> N[Repeat ultrasound<br/>at 28, 32 weeks]:::action ``` ### Why Option 1 (Termination) Is NOT Appropriate **Warning:** Termination is NOT recommended as the first-line management in the second trimester with normal current ultrasound findings. While congenital Zika syndrome is a serious concern, the decision to terminate should be made only after: - Confirmation of Zika infection (RT-PCR/IgM positive) - Serial ultrasounds showing fetal abnormalities - Detailed counselling on prognosis and risks - Parental informed consent ### Why Option 3 (Reassurance) Is Incorrect **Warning:** Vertical transmission occurs at ALL gestational ages, including the second trimester. Zika is teratogenic and poses significant risk of congenital abnormalities. Reassurance without investigation and monitoring is inappropriate and negligent. ### Why Option 4 (IVIG) Is Not Evidence-Based There is **no evidence** that high-dose IVIG prevents Zika vertical transmission or fetal infection. IVIG is not part of standard management for Zika in pregnancy. ### Correct Management: Option 2 **Key Point:** The appropriate next step is: 1. **Confirm diagnosis**: - RT-PCR of serum (most sensitive in acute phase, days 1–5) - RT-PCR of urine (can be positive longer than serum) - Serology: IgM ELISA (positive by day 5–7) 2. **Fetal surveillance**: - **Serial fetal ultrasound** at 2–4 week intervals to detect microcephaly, intracranial calcifications, ventriculomegaly, or other CNS abnormalities - Current ultrasound is reassuring (normal biometry, normal AFV) but does NOT exclude future development of abnormalities 3. **Counselling**: - Discuss risk of congenital Zika syndrome - Explain that risk is lower in second trimester than first, but still significant - Discuss prognosis if fetal abnormalities develop - Offer detailed fetal MRI if ultrasound shows abnormalities ### Diagnostic Timing | Test | Timing | Sensitivity | |------|--------|-------------| | **RT-PCR (serum)** | Days 1–5 | ~95% in acute phase | | **RT-PCR (urine)** | Days 1–14+ | Can detect longer than serum | | **IgM ELISA** | Day 5 onwards | Positive by day 5–7 | | **IgG ELISA** | Week 2 onwards | Indicates past infection | [cite:Harrison 21e Ch 189; CDC Zika Virus Guidelines]